Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity Dronca RS; Jevremovic D; Hanson CA; Rabe KG; Shanafelt TD; Morice WG; Call TG; Kay NE; Collins CS; Schwager SM; Slager SL; Zent CSCytometry B Clin Cytom 2010[]; 78 Suppl 1 (Suppl 1): S35-41BACKGROUND: The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e. CD5+B-CLPD) are poorly defined. METHODS: We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy. RESULTS: We identified 229 patients with CD5+B-CLPD. A definitive pathological diagnosis was made in all 61 (27%) CD5+B-CLPD patients with nonbone marrow (BM) biopsy specimens considered adequate for a comprehensive pathological examination. The most common diagnosis among these 61 patients was CLL (44%) followed by the leukemic phase of marginal zone lymphoma (34%), lymphoplasmacytic lymphoma (11%), diffuse large B cell lymphoma (8%), and high-grade B cell lymphoma not otherwise specified (2%). In contrast, among 168 patients without a non-BM tissue biopsy specimen, a specific diagnosis could be made on review of all available data in only 24 (14%) with 144 (86%) remaining "unclassified." CONCLUSIONS: In patients with CD5+B-CLPD, a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease. We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment.|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|B-Lymphocytes/immunology/metabolism/*pathology[MESH]|Biomarkers/metabolism[MESH]|CD5 Antigens/*metabolism[MESH]|Female[MESH]|Humans[MESH]|Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/immunology/metabolism[MESH]|Lymphoma, B-Cell, Marginal Zone/diagnosis/immunology/metabolism[MESH]|Lymphoma, B-Cell/diagnosis/immunology/metabolism[MESH]|Lymphoma, Large B-Cell, Diffuse/diagnosis/immunology/metabolism[MESH]|Lymphoproliferative Disorders/*diagnosis/immunology[MESH]|Male[MESH]|Middle Aged[MESH]|Prognosis[MESH]|Waldenstrom Macroglobulinemia/diagnosis/immunology/metabolism[MESH]|Young Adult[MESH] |